Log in

NASDAQ:HROWHarrow Health Stock Price, Forecast & News

+0.61 (+12.98 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $5.31
50-Day Range
MA: $4.41
52-Week Range
Now: $5.31
Volume143,400 shs
Average Volume117,602 shs
Market Capitalization$136.04 million
P/E RatioN/A
Dividend YieldN/A
Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HROW



Sales & Book Value

Annual Sales$51.17 million
Book Value$0.59 per share


Net Income$170,000.00


Market Cap$136.04 million
Next Earnings Date8/12/2020 (Estimated)

Receive HROW News and Ratings via Email

Sign-up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.

Harrow Health (NASDAQ:HROW) Frequently Asked Questions

How has Harrow Health's stock been impacted by COVID-19 (Coronavirus)?

Harrow Health's stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HROW shares have increased by 11.6% and is now trading at $5.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Harrow Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harrow Health.

When is Harrow Health's next earnings date?

Harrow Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Harrow Health.

How were Harrow Health's earnings last quarter?

Harrow Health (NASDAQ:HROW) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.45. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.14 million. Harrow Health had a negative net margin of 47.54% and a negative return on equity of 32.90%. View Harrow Health's earnings history.

What price target have analysts set for HROW?

2 analysts have issued 12 month target prices for Harrow Health's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Harrow Health's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price. View analysts' price targets for Harrow Health.

Has Harrow Health been receiving favorable news coverage?

Media stories about HROW stock have trended extremely positive on Wednesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Harrow Health earned a news impact score of 5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutHarrow Health.

Are investors shorting Harrow Health?

Harrow Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,390,000 shares, an increase of 13.0% from the April 30th total of 1,230,000 shares. Based on an average daily volume of 176,500 shares, the short-interest ratio is presently 7.9 days. Currently, 5.9% of the company's stock are sold short. View Harrow Health's Current Options Chain.

Who are some of Harrow Health's key competitors?

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include Corbus Pharmaceuticals (CRBP), Mustang Bio (MBIO), QuickLogic (QUIK), Amarin (AMRN), Canopy Growth (CGC), Crispr Therapeutics (CRSP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Adamis Pharmaceuticals (ADMP) and Agile Therapeutics (AGRX).

Who are Harrow Health's key executives?

Harrow Health's management team includes the following people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 46)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 37)
  • Mr. John P. Saharek, Chief Commercial Officer (Age 59)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.42%), BlackRock Inc. (1.83%), Cadence Capital Management LLC (0.90%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.48%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Harrow Health stock include Opaleye Management Inc and Robert J Kammer. View institutional ownership trends for Harrow Health.

Which major investors are selling Harrow Health stock?

HROW stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Squarepoint Ops LLC, Morgan Stanley, Acadian Asset Management LLC, Russell Investments Group Ltd., Cadence Capital Management LLC, Geode Capital Management LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Harrow Health.

Which major investors are buying Harrow Health stock?

HROW stock was bought by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., Jane Street Group LLC, Advisor Group Holdings Inc., Citigroup Inc., Wells Fargo & Company MN, and BlackRock Inc.. View insider buying and selling activity for Harrow Health.

How do I buy shares of Harrow Health?

Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $5.31.

How big of a company is Harrow Health?

Harrow Health has a market capitalization of $136.04 million and generates $51.17 million in revenue each year. The company earns $170,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

What is Harrow Health's official website?

The official website for Harrow Health is www.harrowinc.com.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 615-733-4730 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.